AI in Healthcare

The latest on artificial intelligence transforming medicine

News stories discovered and organized by an automated pipeline. Covering clinical deployments, research breakthroughs, regulation, and industry developments.

Filtered by: commercializationClear filter
industrykoreabiomed.com

Lunit’s U.S. Breast Cancer Push Shows How Guideline Changes Can Reopen Markets for AI

Korean AI imaging company Lunit is reportedly targeting the U.S. breast cancer risk market after an NCCN guideline update. The move shows how fast-moving clinical guidelines can reshape commercial opportunities for AI vendors. For AI companies, the policy environment is not just a backdrop — it is often the main gatekeeper to adoption.

AIbreast cancer riskNCCNguidelines
industry

TechCrunch: BioticsAI’s FDA Approval and Fundraising Reveal the Hard Part of Building Healthcare Startups

TechCrunch’s profile of BioticsAI focuses on the realities of getting an FDA-cleared healthcare product to market while raising capital. The piece highlights a recurring theme in digital health: regulatory success is necessary, but it is not the same as commercial traction.

TechCrunch
startupFDA approvalfundraising
industry

Philips pushes for proof, scale, and sharing as healthcare AI enters its commercialization phase

Philips is emphasizing evidence generation and replication as the healthcare AI market matures. The message is that vendors will increasingly be judged on demonstrated outcomes, not just technical novelty.

Philips
Philipsevidencecommercialization
industry

AI-Powered Healthcare Won Over Judges at the Edison Awards, but the Real Test Is Adoption

AI healthcare innovations were featured among the winners and standouts at the Edison Awards, reinforcing the sector’s momentum in product design and recognition. Awards may validate novelty and execution, but widespread adoption will depend on integration, reimbursement, and proof of value.

U.S. News & World Report
innovation awardscommercializationhealth tech
industry

BullFrog AI Partnership Highlights the New Pressure on Smaller Discovery Platforms

BullFrog AI’s newly announced drug-discovery partnership underscores how smaller AI companies are seeking validation through targeted collaborations rather than sweeping platform claims. The move reflects a broader market reality: in healthcare AI, commercial credibility increasingly comes from proving fit on specific programs.

TipRanks
BullFrog AIAI drug discoverypartnerships
industry

Pharmaceutical Executive: Lilly-Insilico Deal Shows AI Discovery Is Now a Licensing Business, Not Just a Platform Pitch

Pharmaceutical Executive’s report on the Lilly-Insilico agreement underscores a crucial market shift: AI drug discovery is increasingly monetized through research-and-licensing structures. That indicates buyers want product rights and development options, not just access to software or discovery services.

Pharmaceutical Executive
Pharmaceutical ExecutiveAI drug discoverylicensing
industry

Lilly-Insilico deal spotlights a new commercialization phase for AI-made medicines

STAT reports that Insilico Medicine and Eli Lilly have signed a commercialization-focused agreement worth up to $2.75 billion, extending one of the sector’s most closely watched AI drug discovery relationships. The move is notable less for the headline figure than for what it says about big pharma’s willingness to license AI-originated assets deeper into the pipeline.

statnews.com
Eli LillyInsilico MedicineAI drug discovery
industry

Imaging AI’s Next Commercial Battleground May Be Bespoke, Not Broad

A radiologist-turned-CEO argues that bespoke imaging AI will define the next era of medicine, according to Medical Design & Outsourcing. The claim reflects a growing market reality: broad algorithm portfolios are useful, but health systems increasingly want imaging tools tuned to local workflows, populations, and operational priorities.

Medical Design & Outsourcing
imaging AIradiologymedical devices
industry

Quest Deal Gives HelioLiver a Bigger Shot at Routine Clinical Adoption

Helio Genomics’ agreement to make its HelioLiver test available through Quest Diagnostics’ provider network could materially improve commercial reach for AI-enabled cancer detection. Distribution, ordering access, and physician workflow integration often determine whether diagnostics scale more than the underlying science alone.

PR Newswire
Helio GenomicsQuest DiagnosticsHelioLiver

How this works

Discover

An automated pipeline searches the web for significant AI healthcare news across clinical, research, regulatory, and industry domains.

Structure

The pipeline turns source material into concise, readable stories with categories, tags, and context that make the feed easier to scan.

Publish

Stories are deduplicated, stored, and published to this site. The pipeline runs automatically to keep coverage current.